Search Within

Connie Wing-Ching Lee Batlevi

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (33)
  3. Research Letter (4)
  4. Book Section (1)
  5. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (89)
  2. Department of Medicine (89)
  3. Epidemiology and Biostatistics (89)
  4. Hematologic Malignancies, Division of (89)
  5. Lymphoma (89)
  6. Survivorship Research (76)

More Groups

People
  1. Maria Palomba (65)
  2. Andrew Zelenetz (51)
  3. Anas Younes (49)
  4. Matthew Matasar (48)
  5. Paul Hamlin (42)
  6. Anita Kumar (41)

More People

Years
  1. 2024 (1)
  2. 2023 (9)
  3. 2022 (15)
  4. 2021 (12)
  5. 2020 (17)
  6. 2019 (16)

More Years

Publications
  1. Blood (33)
  2. Blood Advances (12)
  3. Hematological Oncology (8)
  4. Blood Cancer Journal (6)
  5. Journal of Clinical Oncology (5)
  6. Transplantation and Cellular Therapy (4)

More Publications

Publishers
  1. American Society of Hematology (45)
  2. Nature Publishing Group (11)
  3. Elsevier Inc. (10)
  4. Wiley Blackwell (8)
  5. American Society of Clinical Oncology (5)
  6. Taylor & Francis Group (3)

More Publishers

Results (89)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma
    Journal Article

    Fischer, T.; Ni, A.; Bantilan, K. S.; Soumerai, J. D.; Alperovich, A.; Batlevi, C.; Younes, A.; Zelenetz, A. D.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Vitamin D deficiency is associated with inferior clinical outcomes in patients with large B-cell lymphoma receiving anti-CD19 CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Alarcon Tomas, A.; Flynn, J.; Fein, J. A.; Alperovich, A.; Anagnostou, T.; Batlevi, C. W.; Dahi, P. B.; Fingrut, W.; Giralt, S. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy
    Journal Article

    Shouval, R.; Alarcon Tomas, A.; Fein, J. A.; Flynn, J. R.; Markovits, E.; Mayer, S.; Afuye, A. O.; Alperovich, A.; Anagnostou, T.; Besser, M. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Journal Article

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save